GridAI Technologies Corp.

GRDX

Healthcare|Biotechnology|GB

$4.92

+0.25 (+5.35%)

Cash / Share

$0.21

About

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.

Stock Price

+42.2%(1Y)

+2.5%

+79.6%

+43.9%

YTD

+5.6%

+28.1%

-71.6%

-100.0%

Pipeline Summary

0 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Key Facts

Market Cap$35.1M

Employees18 (+800% YoY)

CEOJason David Sawyer

IPO DateOct 11, 2016

Beta1.68

52-Week Range$1.87 – $6.93

Avg Volume102,328

ExchangeNASDAQ

Websitegrid-ai.com

Ownership

Float81.7%

Shares Outstanding7.1M

Recent Insider Trades

Uppal ManpreetAWARD

Oct 19, 202620,000 shares

Syage JackAWARD

Oct 26, 202640,000 shares

Skowron AnnaAWARD

Oct 26, 2026175,000 shares

Skowron AnnaAWARD

Oct 26, 202675,000 shares

Sawyer Jason DavidAWARD

Oct 26, 202640,000 shares

Peers

ALLRAllarity Therapeutics, Inc.

$15.4M

ASBPAspire Biopharma Holdings, Inc.

$933.4K

ATHAAthira Pharma, Inc.

$26.6M

BCTXBriaCell Therapeutics Corp.

$34.5M

CINGCingulate Inc.

$61.9M

CRISCuris, Inc.

$1.8M

CTXRCitius Pharmaceuticals, Inc.

$15.0M

LPTXLeap Therapeutics, Inc.

$31.9M

Data last updated: Nov 9, 2026, 04:12 AM